메뉴 건너뛰기




Volumn 23, Issue SUPPL. 7, 2012, Pages

Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CARVEDILOL; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; IFOSFAMIDE; LAPATINIB; PACLITAXEL; RAZOXANE; SORAFENIB; SUNITINIB; TAMOXIFEN; TRASTUZUMAB; TROPONIN; VALSARTAN; VASCULOTROPIN INHIBITOR;

EID: 84866599720     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds293     Document Type: Article
Times cited : (682)

References (47)
  • 1
    • 84866619380 scopus 로고    scopus 로고
    • Cancer drugs and the heart: importance and management
    • [Epub ahead of print].
    • Suter TM, Ewer MS. Cancer drugs and the heart: importance and management. Eur Heart J. 2012. [Epub ahead of print].
    • (2012) Eur Heart J.
    • Suter, T.M.1    Ewer, M.S.2
  • 2
    • 84873983357 scopus 로고    scopus 로고
    • National Cancer Institute. Cancer therapy evaluation program. [on-line]
    • National Cancer Institute. Cancer therapy evaluation program. [on-line] http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4e30e992.pdf.
  • 3
    • 40749087694 scopus 로고    scopus 로고
    • Cardiac toxicity in breast cancer survivors: review of potential cardiac problems
    • Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: review of potential cardiac problems. Clin Cancer Res. 2008; 14: 14-24.
    • (2008) Clin Cancer Res. , vol.14 , pp. 14-24
    • Bird, B.R.1    Swain, S.M.2
  • 4
    • 0018716636 scopus 로고
    • Risk factors for doxorubicin-induced congestive heart failure
    • Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979; 91: 710-717.
    • (1979) Ann Intern Med. , vol.91 , pp. 710-717
    • Von Hoff, D.D.1    Layard, M.W.2    Basa, P.3
  • 5
    • 0033855860 scopus 로고    scopus 로고
    • Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy
    • Cardinale D, Sandri MT, Martinoni A et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000; 36: 517-522.
    • (2000) J Am Coll Cardiol. , vol.36 , pp. 517-522
    • Cardinale, D.1    Sandri, M.T.2    Martinoni, A.3
  • 6
    • 0035985276 scopus 로고    scopus 로고
    • Myocardial injury revealed by plasma troponin I in breast cancer treatment with high dose chemotherapy
    • Cardinale D, Sandri MT, Martinoni A et al. Myocardial injury revealed by plasma troponin I in breast cancer treatment with high dose chemotherapy. Ann Oncol. 2002; 13: 710-715.
    • (2002) Ann Oncol. , vol.13 , pp. 710-715
    • Cardinale, D.1    Sandri, M.T.2    Martinoni, A.3
  • 7
    • 2942522528 scopus 로고    scopus 로고
    • Prognostic value of Troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy
    • Cardinale D, Sandri MT, Colombo A et al. Prognostic value of Troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004; 109: 2749-2754.
    • (2004) Circulation. , vol.109 , pp. 2749-2754
    • Cardinale, D.1    Sandri, M.T.2    Colombo, A.3
  • 8
    • 17644388763 scopus 로고    scopus 로고
    • Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography
    • Pichon MF, Cvitkovic F, Hacene K et al. Drug-induced cardiotoxicity studied by longitudinal B-type natriuretic peptide assays and radionuclide ventriculography. In Vivo. 2005; 19: 567-576.
    • (2005) In Vivo. , vol.19 , pp. 567-576
    • Pichon, M.F.1    Cvitkovic, F.2    Hacene, K.3
  • 9
    • 0025765631 scopus 로고
    • Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens
    • Braverman AC, Antin JH, Plappert MT et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol. 1991; 9: 1215-1223.
    • (1991) J Clin Oncol. , vol.9 , pp. 1215-1223
    • Braverman, A.C.1    Antin, J.H.2    Plappert, M.T.3
  • 10
    • 0022806838 scopus 로고
    • Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor
    • Goldberg MA, Antin JH, Guinan EC et al. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986; 68: 1114-1118.
    • (1986) Blood. , vol.68 , pp. 1114-1118
    • Goldberg, M.A.1    Antin, J.H.2    Guinan, E.C.3
  • 11
    • 0027455066 scopus 로고
    • High-dose ifosfamide is associated with severe, reversible cardiac dysfunction
    • Quezado ZM, Wilson WH, Cunnion RE et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993; 118: 31-36.
    • (1993) Ann Intern Med. , vol.118 , pp. 31-36
    • Quezado, Z.M.1    Wilson, W.H.2    Cunnion, R.E.3
  • 12
    • 21144435932 scopus 로고    scopus 로고
    • Adjuvant docetaxel for node-positive breast cancer
    • Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005; 352: 2302-2313.
    • (2005) N Engl J Med. , vol.352 , pp. 2302-2313
    • Martin, M.1    Pienkowski, T.2    Mackey, J.3
  • 13
    • 80053539103 scopus 로고    scopus 로고
    • Adjuvant trastuzumab in HER2-positive breast cancer
    • Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011; 365(14): 1273-1283.
    • (2011) N Engl J Med. , vol.365 , Issue.14 , pp. 1273-1283
    • Slamon, D.1    Eiermann, W.2    Robert, N.3
  • 14
    • 26844536978 scopus 로고    scopus 로고
    • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    • Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684.
    • (2005) N Engl J Med. , vol.353 , pp. 1673-1684
    • Romond, E.H.1    Perez, E.A.2    Bryant, J.3
  • 15
    • 26844503270 scopus 로고    scopus 로고
    • Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    • Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672.
    • (2005) N Engl J Med. , vol.353 , pp. 1659-1672
    • Piccart-Gebhart, M.J.1    Procter, M.2    Leyland-Jones, B.3
  • 16
    • 0035869407 scopus 로고    scopus 로고
    • Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    • Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
    • (2001) N Engl J Med. , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 17
    • 29744442709 scopus 로고    scopus 로고
    • Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31
    • Tan-Chiu E, Yothers G, Romond E et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005; 23: 7811-7819.
    • (2005) J Clin Oncol. , vol.23 , pp. 7811-7819
    • Tan-Chiu, E.1    Yothers, G.2    Romond, E.3
  • 18
    • 41649083764 scopus 로고    scopus 로고
    • Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial
    • Perez EA, Suman VJ, Davidson NE et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008; 26: 1231-1238.
    • (2008) J Clin Oncol. , vol.26 , pp. 1231-1238
    • Perez, E.A.1    Suman, V.J.2    Davidson, N.E.3
  • 19
    • 34548531901 scopus 로고    scopus 로고
    • Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial
    • Suter TM, Procter M, van Veldhuisen DJ et al. Trastuzumab-associated cardiac adverse effects in the Herceptin adjuvant trial. J Clin Oncol. 2007; 25: 3859-3865.
    • (2007) J Clin Oncol. , vol.25 , pp. 3859-3865
    • Suter, T.M.1    Procter, M.2    van Veldhuisen, D.J.3
  • 20
    • 33344478381 scopus 로고    scopus 로고
    • Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
    • Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006; 354: 809-820.
    • (2006) N Engl J Med. , vol.354 , pp. 809-820
    • Joensuu, H.1    Kellokumpu-Lehtinen, P.L.2    Bono, P.3
  • 21
    • 37549040613 scopus 로고    scopus 로고
    • Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    • Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357: 2666-2676.
    • (2007) N Engl J Med. , vol.357 , pp. 2666-2676
    • Miller, K.1    Wang, M.2    Gralow, J.3
  • 22
    • 44949253343 scopus 로고    scopus 로고
    • Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials
    • Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008; 83: 679-686.
    • (2008) Mayo Clin Proc. , vol.83 , pp. 679-686
    • Perez, E.A.1    Koehler, M.2    Byrne, J.3
  • 23
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007; 356: 115-124.
    • (2007) N Engl J Med. , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 24
    • 78650383580 scopus 로고    scopus 로고
    • Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology
    • Eschenhagen T, Force T, Ewer M et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2011; 13: 1-10.
    • (2011) Eur J Heart Fail. , vol.13 , pp. 1-10
    • Eschenhagen, T.1    Force, T.2    Ewer, M.3
  • 25
    • 61749084637 scopus 로고    scopus 로고
    • Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring
    • Jones AL, Barlow M, Barrett-Lee PJ et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer. 2009; 100: 684-692.
    • (2009) Br J Cancer. , vol.100 , pp. 684-692
    • Jones, A.L.1    Barlow, M.2    Barrett-Lee, P.J.3
  • 26
    • 61449181370 scopus 로고    scopus 로고
    • Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations
    • Martin M, Esteva FJ, Alba E et al. Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 2009; 14: 1-11.
    • (2009) Oncologist , vol.14 , pp. 1-11
    • Martin, M.1    Esteva, F.J.2    Alba, E.3
  • 27
    • 78649907467 scopus 로고    scopus 로고
    • Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage
    • Geisberg CA, Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep. 2010; 12: 404-410.
    • (2010) Curr Hypertens Rep. , vol.12 , pp. 404-410
    • Geisberg, C.A.1    Sawyer, D.B.2
  • 28
    • 77957567061 scopus 로고    scopus 로고
    • Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation
    • Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010; 28: 3910-3916.
    • (2010) J Clin Oncol. , vol.28 , pp. 3910-3916
    • Cardinale, D.1    Colombo, A.2    Torrisi, R.3
  • 29
    • 33845402341 scopus 로고    scopus 로고
    • Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition
    • Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensinconverting enzyme inhibition. Circulation. 2006; 114: 2474-2481.
    • (2006) Circulation. , vol.114 , pp. 2474-2481
    • Cardinale, D.1    Colombo, A.2    Sandri, M.T.3
  • 31
    • 33845206791 scopus 로고    scopus 로고
    • Protective effects of carvedilol against anthracyclines-induced cardiomyopathy
    • Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracyclines-induced cardiomyopathy. J Am Coll Cardiol. 2006; 48: 2258-2262.
    • (2006) J Am Coll Cardiol. , vol.48 , pp. 2258-2262
    • Kalay, N.1    Basar, E.2    Ozdogru, I.3
  • 32
    • 28044442932 scopus 로고    scopus 로고
    • Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone
    • Nakamae H, Tsumura K, Terada Y et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005; 104: 2492-2498.
    • (2005) Cancer. , vol.104 , pp. 2492-2498
    • Nakamae, H.1    Tsumura, K.2    Terada, Y.3
  • 33
    • 77957241407 scopus 로고    scopus 로고
    • Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus continuous infusion
    • Huh WW, Jaffe N, Durand JB et al. Comparison of doxorubicin cardiotoxicity in pediatric sarcoma patients when given with dexrazoxane versus continuous infusion. Pediatr Hematol Oncol. 2010; 27: 546-557.
    • (2010) Pediatr Hematol Oncol. , vol.27 , pp. 546-557
    • Huh, W.W.1    Jaffe, N.2    Durand, J.B.3
  • 34
    • 0036018917 scopus 로고    scopus 로고
    • Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil
    • Van Cutsem E, Hoff PM, Blum JL et al. Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol. 2002; 13: 484-485.
    • (2002) Ann Oncol. , vol.13 , pp. 484-485
    • Van Cutsem, E.1    Hoff, P.M.2    Blum, J.L.3
  • 35
    • 0025799973 scopus 로고
    • Cardiac disturbances during the administration of taxol
    • Rowinsky EK, McGuire WP, Guarnieri T et al. Cardiac disturbances during the administration of taxol. J Clin Oncol. 1991; 9: 1704-1712.
    • (1991) J Clin Oncol. , vol.9 , pp. 1704-1712
    • Rowinsky, E.K.1    McGuire, W.P.2    Guarnieri, T.3
  • 36
    • 38049095554 scopus 로고    scopus 로고
    • Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Metaanalysis of randomized trials
    • Cuppone F, Bria E, Verma S et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Metaanalysis of randomized trials. Cancer 2008; 112: 260-267.
    • (2008) Cancer , vol.112 , pp. 260-267
    • Cuppone, F.1    Bria, E.2    Verma, S.3
  • 37
    • 55949123335 scopus 로고    scopus 로고
    • Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma
    • Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2008; 26: 5204-5212.
    • (2008) J Clin Oncol. , vol.26 , pp. 5204-5212
    • Schmidinger, M.1    Zielinski, C.C.2    Vogl, U.M.3
  • 38
    • 34250365240 scopus 로고    scopus 로고
    • Mechanisms of adverse effects of anti-VEGF therapy for cancer
    • Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007; 96: 1788-1795.
    • (2007) Br J Cancer. , vol.96 , pp. 1788-1795
    • Kamba, T.1    McDonald, D.M.2
  • 39
    • 34249294557 scopus 로고    scopus 로고
    • Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
    • Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer. 2007; 7: 475-485.
    • (2007) Nat Rev Cancer. , vol.7 , pp. 475-485
    • Verheul, H.M.1    Pinedo, H.M.2
  • 40
    • 33645449812 scopus 로고    scopus 로고
    • Mechanisms of hypertension associated with BAY 43-9006
    • Veronese ML, Mosenkis A, Flaherty KT et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol. 2006; 24: 1363-1369.
    • (2006) J Clin Oncol. , vol.24 , pp. 1363-1369
    • Veronese, M.L.1    Mosenkis, A.2    Flaherty, K.T.3
  • 42
    • 40249094483 scopus 로고    scopus 로고
    • Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development
    • Curigliano G, Spitaleri G, Fingert HJ et al. Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development. Eur J Cancer. 2008; 44(4): 494-500.
    • (2008) Eur J Cancer. , vol.44 , Issue.4 , pp. 494-500
    • Curigliano, G.1    Spitaleri, G.2    Fingert, H.J.3
  • 43
    • 0035818552 scopus 로고    scopus 로고
    • Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia
    • Barbey JT, Soignet S. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med. 2001; 135: 842-843.
    • (2001) Ann Intern Med. , vol.135 , pp. 842-843
    • Barbey, J.T.1    Soignet, S.2
  • 44
    • 0041352835 scopus 로고    scopus 로고
    • Asymptomatic cardiac disease following mediastinal irradiation
    • Heidenreich PA, Hancock SL, Lee BK et al. Asymptomatic cardiac disease following mediastinal irradiation. J Am Coll Cardiol. 2003; 42: 743-749.
    • (2003) J Am Coll Cardiol. , vol.42 , pp. 743-749
    • Heidenreich, P.A.1    Hancock, S.L.2    Lee, B.K.3
  • 45
    • 27744581889 scopus 로고    scopus 로고
    • Diastolic dysfunction after mediastinal irradiation
    • Heidenreich PA, Hancock SL, Vagelos RH et al. Diastolic dysfunction after mediastinal irradiation. Am Heart J. 2005; 150: 977-982.
    • (2005) Am Heart J. , vol.150 , pp. 977-982
    • Heidenreich, P.A.1    Hancock, S.L.2    Vagelos, R.H.3
  • 46
    • 78751511293 scopus 로고    scopus 로고
    • Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation
    • Galper SL, Yu JB, Mauch PM et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011; 117(2): 412-418.
    • (2011) Blood , vol.117 , Issue.2 , pp. 412-418
    • Galper, S.L.1    Yu, J.B.2    Mauch, P.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.